Nima Sharifi
@nimasharifimd
Prostate Cancer Medical Oncologist & Scientific Director, Desai Sethi Urology Institute, Sylvester Cancer Center, University of Miami Miller School of Medicine
ID: 2921955274
http://nimasharifilab.com 14-12-2014 20:22:42
6,6K Tweet
4,4K Followers
959 Following
Pedro Freitas brings so much energy, enthusiasm, innovation and fun - to OR to bench translational studies! There is so much to look forward to! Pedro F. S. Freitas, MD Desai Sethi Urology Institute
It's been truly exciting, Dr. Nima Sharifi ! The OR definitely brings unique research opportunities.
Taylor Lab UM Sylvester Comprehensive Cancer Center Ash Alizadeh, MD/PhD 🇺🇸 Andy Lane Stephen D. Nimer, MD Abdel-Wahab Lab Miller Medicine ASCI Nima Sharifi Dr. Maria “Ken” Figueroa We would like to inform you that your post has been published on OncoDaily.com. Thank you for sharing oncodaily.com/career/227834
Join us for a dynamic lineup of speakers and sessions at the 2nd Annual Miami Symposium on Human Metabolism led by Nima Sharifi Sylvester Comprehensive Cancer Center Saturday, February 8th, 2025 med.miami.edu/elp/miamimetab…
Exceptional visit to the Sylvester Comprehensive Cancer Center and see so many friends! Great meetings and feedback on a lot of our ongoing work! #Collaboration - Defne Bayik Dionysios (Dennis) Watson Scott Welford Nima Sharifi Ashish H. Shah
Tomorrow is the day! Looking forward to an exciting day of human #metabolism science! Desai Sethi Urology Institute
Full house for the Miami Symposium on Human Metabolism! Nima Sharifi kicking off an exciting day talking about science! Desai Sethi Urology Institute #MSHM
Had a fantastic time at the 2025 Desai Sethi Urology Institute Miami Symposium of Human Metabolism! Insightful discussions on the intersections of metabolism, aging, and cancer from experts across the country and overseas. And great opportunity to meet friends from Nima Sharifi Lab!
Talazoparib + enzalutamide improved OS in all patients on TALAPRO-2, beyond just those with HRR alts, against enza. Presented by PI Neeraj Agarwal, MD, FASCO at #GUASCO25 Compelling argument that AR antagonist have synergy with PARPi
Examining racial differences in OATP and outcomes in castration-resistant prostate cancer treated with AR pathway inhibitors in the Alliance A031201 phase III trial. 🌍🔬 Charles Ryan Nima Sharifi ASCO #GU25
#GU25 Nima Sharifi using the ALLIANCE platform evaluated Adrenal androgens and OS in men with CRPC treated with ENZA +/- AAP. Key insights included: 🚩 n=929 men who had germline DNA genotyped for HSD3B1. Baseline DHEA, testosterone and androstenedione assessed n=922 men 🚩
Adrenal androgens and OS in men with #CRPC treated with enzalutamide without or with abiraterone and prednisone #Alliance. Presentation by Nima Sharifi Desai Sethi Urology Institute. #GU25 written coverage by Julian Chavarriaga University of Toronto > bit.ly/4gKSkfB
Intriguing work by Nima Sharifi dissecting negative impact of adrenal permissive HSD3B1 genotype on outcomes in patients with HSPC. #GU25
We found out last night that the study section scheduled to review our R01 resubmission was cancelled 24hrs before the review. We spent months conducting experiments, writing and revising this proposal for prostate cancer research that represents 4 years of work. National Cancer Institute NIH
Please save the Department of Defense 🇺🇸 Prostate Cancer Research Program! We need continued funding to keep fighting #ProstateCancer Senator Alex Padilla Adam Schiff Rep. Mike Levin UroToday.com PCF Science Howard Soule Andrea Miyahira Uromigos
Thrilled to share our UM SVI LAB work published today in Journal of Clinical Investigation focused on harnessing viral mimicry to activate immunotherapy for #GBM. Thanks to all of my Sylvester Comprehensive Cancer Center UM Neurosurgery colleagues for their invaluable contributions! jci.org/articles/view/…
